Healios K.K. (HLOSF) Stock Price, News & Analysis

Company Overview

Healios K.K. is a Tokyo–based biotechnology company focused on the development and commercialization of regenerative medicine products and services. The company’s core expertise lies in induced pluripotent stem cell (iPSC)–derived therapies, with a pipeline that includes retinal pigment epithelium (RPE) cells for age‐related macular degeneration and neural cell products targeting neurological disorders. Healios operates a specialized cell processing center in Chuo‐ku, Tokyo, adhering to stringent quality standards for clinical‐grade cell manufacturing.

Beyond its proprietary programs, Healios provides contract development and manufacturing services (CDMO) to pharmaceutical and research institutions. These offerings span process development, cell banking, scale‐up production, and analytical testing, all designed to support clients from early‐stage research through late‐stage clinical trials. The company’s integrated platform enables efficient translation of cell‐based therapies under Japanese and international regulatory frameworks.

Since its establishment in 2016, Healios has formed strategic collaborations with academia, healthcare institutions, and biopharma partners to advance its regenerative medicine portfolio. It has received multiple designations and grants from the Japan Pharmaceuticals and Medical Devices Agency (PMDA), underscoring its commitment to innovative therapeutic solutions. While its primary operations serve the Japanese market, Healios is actively exploring global partnerships to extend the reach of its cell therapy technologies.

Governed by a leadership team with deep experience in biopharmaceutical development and cell therapy commercialization, Healios continues to build its capabilities in translational research and manufacturing. The company’s management is focused on progressing its clinical pipeline, expanding its CDMO offerings, and fostering alliances that drive sustainable growth in the rapidly evolving field of regenerative medicine.

Key Stats

• Today's Range: $1.80 to $1.80
• 50-Day Range: $1.80 to $1.80
• 52-Week Range: $1.80 to $4.45
• Volume: N/A
• Average Volume: 300 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 8/05/2026
• Next Earnings (Estimated): 8/12/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:HLOSF
• CIK: N/A
• Web: healios.co.jp
• Phone: 81357778308
• Fax: N/A
• Employees: 64
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A